The current financial score of Aptevo Therapeutics Inc is 6.84. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Aptevo Therapeutics Inc is 9.15. Its current P/E ratio is 0.00, which is 134391.67% below the recent high of 1.61 and 46108.33% above the recent low of -0.55.
The current earnings forecast score of Aptevo Therapeutics Inc is 8.00. The average price target is 25.50, with a high of 30.00 and a low of 21.00.
The current price momentum score of Aptevo Therapeutics Inc is 6.42. Currently, the stock price is trading between the resistance level at 2.62 and the support level at 1.22, making it suitable for range-bound swing trading.
The current institutional shareholding score of Aptevo Therapeutics Inc is 3.00. The latest institutional shareholding proportion is 4.71%, representing a quarter-over-quarter increase of 1847.48%.
The current risk assessment score of Aptevo Therapeutics Inc is 1.89. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.